About
Perpetually Active Peptides
Areas of Focus
Categories
Biologics & BiopharmaceuticalGene Therapy, RNA & Peptide TherapySouthwestern U.S.
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
259
By Phase
PHASE2: 2PHASE1: 2
By Status
COMPLETED: 3ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06968845Lead Sponsor
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
PHASE2Active, not recruiting
120 participants
Started: May 2, 2025 · Completed: May 28, 2027
NCT05954988Lead Sponsor
A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients
PHASE1Completed
24 participants
Started: Jul 6, 2023 · Completed: Sep 25, 2024
NCT04159831Lead Sponsor
A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions
PHASE2Completed
44 participants
Started: Sep 26, 2020 · Completed: Jul 28, 2022
NCT04233814Lead Sponsor
Safety, Tolerability and Pharmacokinetic Study of LTI-03 in Healthy Adult Subjects
PHASE1Completed
71 participants
Started: Jan 20, 2020 · Completed: Dec 23, 2021
Locations (1)
Headquarters
Austin, TX, United States
Map
Loading map...